We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

110 hedge funds and large institutions have $98.2M invested in iShares US Pharmaceuticals ETF in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

9% more funds holding

Funds holding: 101 → 110 (+9)

0.95% more ownership

Funds ownership: 77.5% → 78.45% (+0.95%)

0% less capital invested

Capital invested by funds: $98.4M → $98.2M (-$139K)

12% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 26

Holders
110
Holders Change
+9
Holders Change %
+8.91%
% of All Funds
1.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
23
Reduced
26
Closed
5
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$6K

Top Buyers

1
Osaic Holdings
Osaic Holdings
Arizona
+$1.72M
2
FTUS
Flow Traders U.S.
New York
+$939K
3
IWC
Integrated Wealth Concepts
Massachusetts
+$884K
4
AWM
AE Wealth Management
Kansas
+$669K
5
Morgan Stanley
Morgan Stanley
New York
+$354K

Top Sellers

1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.37M
2
UBS Group
UBS Group
Switzerland
-$2.21M
3
Bank of America
Bank of America
North Carolina
-$991K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$228K
5
AFG
Arkansas Financial Group
Arkansas
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
1
Wells Fargo
California
$11.2M +$180K +2,826 +2%
Morgan Stanley
2
Morgan Stanley
New York
$8.69M +$354K +5,568 +4%
Citadel Advisors
3
Citadel Advisors
Florida
$7.63M +$266K +4,188 +3%
Royal Bank of Canada
4
Royal Bank of Canada
Ontario, Canada
$6.97M -$2.37M -37,356 -25%
Brown Advisory
5
Brown Advisory
Maryland
$6.87M -$19.1K -300 -0.3%
RJA
6
Raymond James & Associates
Florida
$5.51M +$174K +2,736 +3%
Bank of America
7
Bank of America
North Carolina
$4.79M -$991K -15,582 -17%
LPL Financial
8
LPL Financial
California
$4.52M +$155K +2,439 +3%
MCM
9
Murphy Capital Management
New Jersey
$3.42M -$42.9K -675 -1%
SPIA
10
Steward Partners Investment Advisory
New York
$3.04M +$146K +2,304 +5%
Commonwealth Equity Services
11
Commonwealth Equity Services
Massachusetts
$2.79M -$9.92K -156 -0.3%
Osaic Holdings
12
Osaic Holdings
Arizona
$2.72M +$1.72M +26,985 +154%
UBS Group
13
UBS Group
Switzerland
$1.99M -$2.21M -34,824 -52%
Envestnet Asset Management
14
Envestnet Asset Management
Illinois
$1.64M +$9.92K +156 +0.6%
Fisher Asset Management
15
Fisher Asset Management
Washington
$1.42M +$88.7K +1,395 +6%
CFA
16
Cahill Financial Advisors
Minnesota
$1.29M – – –
ST
17
Spinnaker Trust
Maine
$1.19M -$55.7K -876 -4%
BPA
18
Beacon Pointe Advisors
California
$1.17M +$199K +3,126 +20%
Truist Financial
19
Truist Financial
North Carolina
$1.17M +$55.9K +879 +5%
PP
20
Patten & Patten
Tennessee
$1.1M -$7.63K -120 -0.7%
Janney Montgomery Scott
21
Janney Montgomery Scott
Pennsylvania
$953K -$162K -2,541 -14%
FTUS
22
Flow Traders U.S.
New York
$902K +$939K +14,778 New
TFF
23
The Family Firm
Maryland
$885K +$136K +2,133 +18%
TYCC
24
Texas Yale Capital Corp
Florida
$881K – – –
IWC
25
Integrated Wealth Concepts
Massachusetts
$849K +$884K +13,908 New
1
2 3 4 5

IHE Hedge Fund Activity: Q3 2021 in Review

110 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2021, worth a combined $98.2M — down 0.14% from $98.4M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IHE positions and 5 closed out — a net gain of 9 holders — while 23 added to existing stakes and 26 trimmed.

The largest buyer was Osaic Holdings, adding an estimated $1.72M. The largest seller was Royal Bank of Canada, cutting an estimated $2.37M.

  • 110 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2021, up from 101 in Q2 2021.
  • Funds reported $98.2M of iShares US Pharmaceuticals ETF stock for Q3 2021, down 0.14% quarter-over-quarter.
  • 14 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2021 and 5 closed out, a net change of +9 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2021 was Osaic Holdings, an estimated $1.72M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2021 was Royal Bank of Canada, an estimated $2.37M sold.

Based on aggregated 13F filings for Q3 2021.